Evidence supporting paracrine hypothesis for Akt‐modified mesenchymal stem cell‐mediated cardiac protection and functional improvement

By M. Gnecchi, Huamei He, N. Noiseux, Olin D. Liang, Lunan Zhang, F. Morello, H. Mu, L. Melo, R. Pratt, J. Ingwall and 1 more. The FASEB Journal, 2006

1,191 citations recorded by the source corpus.

Subfields: Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/2b661696bc9a5fb24494abf9ab976fa98b8cf0c9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Charles E. Murry
2. J. Karp

In Surgery

1. Charles E. Murry
2. M. Laflamme
3. J. Karp
4. Nikolaos G. Frangogiannis
5. H. Ruskoaho
6. Virpi Talman
7. G. Keller

Citations in the corpus

• Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. (2010, background): “Recent reports have suggested that some of these reparative effects are mediated by paracrine factors secreted by MSCs (Caplan and Dennis, 2006a; Gnecchi et al., 2005, 2006; Schafer and Northoff, 2008).”
• Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. (2013, background): “Since then, theparacrine effect ofMSCswas observed inmany animalmodels of tissue injury including acutemyocardial infarction [100], reperfusion injury [101], ischemic acute renal failure [102],wound healing [103], skeletal tissue repair [104], acute kidney injury [105] and hypoxic pulmonary vasocons”
• Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. (2013, neutral): “It has been shown that mesenchymal stem cell-conditioned medium (MSC-CM) enhances cardio-myocyte and/or progenitor survival after hypoxia-induced injury (Chimenti et al., 2010; Deuse et al., 2009; Gnecchi et al., 2006; Matsuura et al., 2009; Rogers et al., 2011).”
• Harnessing the Mesenchymal Stem Cell Secretome for the Treatment of Cardiovascular Disease (2012, background): “MSCs induce myocardial protection by promoting cardiomyocyte survival and preventing apoptosis through activation of PKC, PI3K/Akt, NF-kB, and STAT3 signaling (Gnecchi et al., 2008; Mirotsou et al., 2011).”
• Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts (2007, background): “There is evidence that transplanted cells produce paracrine factors that enhance survival of host cardiomyocytes postinfarctio”
• Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. (2008, background): “Recent reports suggest that some of the therapeutic effects of MSCs are mediated by paracrine factors secreted by these cells (Caplan and Dennis, 2006; Gnecchi et al., 2005; Gnecchi et al., 2006).”
• Challenges and advances in clinical applications of mesenchymal stromal cells (2021, background): “This hypothesis was then confirmed by evident improvements in cardiac performance following injection of conditioned medium (CM) collected from hypoxic Akt-MSCs into an induced MI model, which protected ventricular cardiomyocytes with less apoptosis when subjected to a hypoxic condition [92].”
• Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model (2013, result): “Consistent with the previous observations [35, 36], our results showed that MSC treatment displayed a beneficial effect on the infarcted heart in a rat model.”